stoxline Quote Chart Rank Option Currency Glossary
  
Benitec Biopharma Inc. (BNTC)
9.02  -0.39 (-4.14%)    05-24 16:00
Open: 9.52
High: 9.56
Volume: 11,148
  
Pre. Close: 9.41
Low: 9.02
Market Cap: 84(M)
Technical analysis
2024-05-27 4:44:30 PM
Short term     
Mid term     
Targets 6-month :  12.49 1-year :  14.59
Resists First :  10.69 Second :  12.49
Pivot price 9.05
Supports First :  8.08 Second :  6.46
MAs MA(5) :  9.59 MA(20) :  8.87
MA(100) :  5.25 MA(250) :  4.11
MACD MACD :  0.7 Signal :  0.8
%K %D K(14,3) :  56.9 D(3) :  64.5
RSI RSI(14): 56.2
52-week High :  10.69 Low :  1.86
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ BNTC ] has closed above bottom band by 48.4%. Bollinger Bands are 49.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 31 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 9.57 - 9.64 9.64 - 9.69
Low: 8.85 - 8.94 8.94 - 9.01
Close: 8.9 - 9.02 9.02 - 9.11
Company Description

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Headline News

Thu, 23 May 2024
Benitec Biopharma (BNTC) Price Target Increased by 66.67% to 10.20 - MSN

Mon, 13 May 2024
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update - Yahoo Finance

Wed, 01 May 2024
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference - Yahoo Finance

Fri, 19 Apr 2024
Benitec Biopharma's $40 Million Equity Financing Deal - TipRanks.com - TipRanks

Fri, 19 Apr 2024
Benitec Biopharma reports progress in OPMD gene therapy trial - Investing.com Australia

Thu, 18 Apr 2024
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b ... - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 9 (M)
Held by Insiders 1.57e+006 (%)
Held by Institutions 10.4 (%)
Shares Short 11 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.16e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -35 %
Return on Assets (ttm) 560.6 %
Return on Equity (ttm) -81.6 %
Qtrly Rev. Growth 61000 %
Gross Profit (p.s.) 0
Sales Per Share -220.13
EBITDA (p.s.) 0
Qtrly Earnings Growth -236.2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -18 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.05
Price to Cash Flow 1.22
Stock Dividends
Dividend 0
Forward Dividend 98530
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android